36 results about "Bispecific monoclonal antibody" patented technology

The invention provides anti-CD47 antibodies and methods of use thereof. The invention relates to monoclonal and / or monovalent antibodies that bind CD47. The invention relates to monoclonal and / or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

The plant-based production of a therapeutic antibody against West Nile Virus is disclosed.

The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies. The invention provides a mean of producing a fully human bispecific and bivalent antibody that is unaltered in sequence and does not involve the use of linkers or other non-human sequences, as well as antibody mixtures of two monospecific antibodies and one bispecific antibody. The invention also provides the means of efficiently purifying the bispecific antibody.

The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and / or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.

Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.

The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and / or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and / or on CD8+ T-cells and / or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition / medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and / or on CD8+ T-cells and / or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors.host cells, methods for the production of the (bispecific) antibody molecule as well as a kit comprising the (bispecific) antibody molecule of the invention.

The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the immune system to fight the cancer or HIV-1 infections. The present invention also discloses multivalent polypeptides which specifically bind to and enable destruction and / or inactivation of immune cells that have CD11b and CD3 on their surface, therefore dissipating the deleterious effects of the CD11b+T cells.

The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

The invention relates to a bispecific monoclonai antibody capable of simultaneously recognizing imidacloprid and parathion-methyl pesticides, and a preparation method thereof, belonging to the field of biological technology. The bispecific monoclonai antibody FQ-D6 which can be stably secreted and simultaneously resist imidacloprid and parathion-methyl pesticides is prepared by fusing hybridoma cell capable of secreting anti-parathion-methyl monoclonal antibody and an imidacloprid antigen-immunized rat splenocyte cell through a hydridizatio-hybridoma technique. Proved by effectiveness verification, the antibody can be used for fast and sensitively detecting residuals of the parathion-methyl and the imidacloprid in agricultural production environment and agricultural products. The preparation technology of the bispecific monoclonai antibody capable of simultaneously resisting imidacloprid and parathion-methyl pesticides is simple, convenient and feasible, the whole preparation process of the antibody is not required for special instruments and equipment, thereby being easy for factorization scale production.

The invention relates to a plasmodium antibody colloidal gold detection kit and a preparation method thereof. The plasmodium antibody colloidal gold detection kit comprises reagent strips, namely a piece of sample filter paper, an immune colloidal gold paper sheet, an immune nitrocellulose membrane and a piece of water absorption paper sequentially from a sample injection end, wherein an HRPII-pLDH bispecific monoclonal antibody marked by colloidal gold is wrapped on the immune colloidal gold paper sheet; an anti-HRPII specific monoclonal antibody and an anti-pLDH specific monoclonal antibody are sprayed in a detection region (T) of the nitrocellulose membrane; and goat-anti-mouse immune globulin (IgG) is sprayed in a quality control region (C) of the nitrocellulose membrane. The plasmodium antibody colloidal gold detection kit can detect Malaria sensitively, specifically and quickly.